The earnings disappointment was the catalyst needed to take profits after a tremendous run since
November. After the sell-off past two days, looking for a rebound back above $2 by end of next week.
I also expect some significant contracts to be announced in August.
I have been a shareholder since June 2013. The first year was great but the last two have really tested my patience despite progress that the company has been making.
Investing in biotech is not for the impatient or those with a short term outlook (less than five years). Like many, I have had visions of the share price popping to $50 or more by 2017. Well, this is not likely to happen because the trials and approval process does take years. And since shorts love volatile stocks and sectors, small biotech companies like Inovio are easily manipulated in the markets, even when there is seemingly
People complain that management does not share enough information with its shareholders. I believe they do not share unless they are required to do so. Too many times I have seen CEOs of other companies tweet and make comments (eg. CNBC) and rarely seen a favorable outcome regarding share price of their company stock.
With the absence of information and long gaps in PRs, an investor has to look at other tangible clues to get
an idea of the confidence that management has in the future. The obvious indicator is employment and Inovio has been growing steadily. The other is insider buying and last I checked there has been some buying by management and very little selling of shares.
Earnings coming up end of month. Look for another quarter of excellent results. This one is headed to $10 in 2017. Not a lot of hype because the climb has been steady without a lot of volatility. Should be back to $3.00 by end of July.